Mapping Childhood Cancer Survival in India: Landmark AIIMS Study Reveals Wide Outcome Gaps and Critical Need for Long-Term Care

NEW DELHI — In the first comprehensive attempt to map childhood cancer survival across India, a new landmark study led by researchers at the All India Institute of Medical Sciences (AIIMS), New Delhi, offers a detailed look at pediatric oncology outcomes over the past three decades. The findings reveal a landscape of striking contrasts: while advances in treatment have pushed survival rates remarkably high for certain malignancies, outcomes for other pediatric cancers remain starkly diminished—underscoring significant gaps in early detection, treatment access, and post-remission care.

Published in JCO Global Oncology on July 26, 2026, the systematic scoping review synthesized data from 182 studies conducted across Indian medical centers, encompassing a total cohort of 22,886 pediatric patients. By aggregating thirty years of published literature, the AIIMS-led team has established a crucial baseline for clinicians, researchers, and public health policymakers striving to standardize cancer care across the country.

A Tale of Two Realities: The Findings

The review demonstrates that survival rates in India vary dramatically depending on the specific type of cancer and the stage at which it is diagnosed.

For highly treatable conditions, the numbers reflect encouraging progress:

• Hodgkin Lymphoma: Achieved a five-year overall survival rate of 93.1%.

• Wilms Tumor: A localized kidney cancer, registered a five-year overall survival rate of 78.8%.

• Retinoblastoma: A rare eye cancer, showed a five-year overall survival rate of 76.8%.

• Acute Lymphoblastic Leukemia (ALL): The most common pediatric blood cancer, demonstrated a five-year overall survival rate of 67.1%.

Intermediate-term survival data similarly highlighted strong outcomes for select hematologic conditions. The estimated three-year overall survival rate reached 97% for chronic myeloid leukemia and 60.9% for acute myeloid leukemia.

       5-Year Overall Survival Rates by Cancer Type (AIIMS Meta-Analysis)
       
  Hodgkin Lymphoma  [#################################################] 93.1%
       Wilms Tumor  [######################################] 78.8%
    Retinoblastoma  [#####################################] 76.8%
     Leukemia (ALL) [###################] 67.1%
                    +---------+---------+---------+---------+---------+
                    0%        20%       40%       60%       80%      100%

However, the report presents a sobering contrast for solid tumors and aggressive malignancies:

• Neuroblastoma: Three-year overall survival stood at 56.9%.

• Osteosarcoma: A primary bone cancer, saw a three-year overall survival of 60.3%.

• Medulloblastoma: A malignant brain tumor, demonstrated a median overall survival of 43.9 months.

• Ewing Sarcoma: Recorded a median overall survival of just 21.2 months.

Crucially, the report highlighted how late presentation severely impacts prognosis. Children diagnosed with extraocular retinoblastoma—where the cancer has metastasized beyond the eye—experienced a pooled two-year overall survival of just 44.9%, compared to the much higher overall rates for localized disease.

“This review represents the first comprehensive synthesis of published childhood cancer survival evidence from India,” said Dr. Sameer Bakhshi, Professor and Head of the Department of Medical Oncology at AIIMS New Delhi and the study’s corresponding author. “It systematically identifies critical gaps in our current knowledge and highlights where urgent public health interventions are required.”

Two Lenses on Pediatric Oncology

To fully comprehend the landscape of pediatric oncology in India, experts emphasize evaluating these findings alongside other recent national research.

Complementing the AIIMS scoping review is the Indian Childhood Cancer Survivorship (C2S) study, recently published in Lancet Regional Health – Southeast Asia. Tracking a cohort of 5,419 pediatric survivors across 20 specialized centers, the C2S study reported a five-year overall survival rate of 94.5%.

While these two figures—67.1% for ALL in the AIIMS review versus 94.5% in the C2S cohort—might initially appear contradictory, oncologists clarify that they measure two distinct phases of the cancer journey:

1. The AIIMS Scoping Review aggregates broad population data representing all children diagnosed at various centers, reflecting real-world treatment challenges, dropouts, and initial mortality.

2. The C2S Survivorship Cohort specifically tracks children who have successfully completed initial therapy and entered remission, evaluating their long-term survival and health.

Together, these studies illustrate that while curative therapies are highly effective when successfully delivered, overcoming initial barriers—such as late presentation, treatment abandonment, and unequal access to specialized tertiary care—remains a formidable hurdle.

Public Health Implications: Beyond the Cure

For public health officials, the findings signal a clear imperative: curing pediatric cancer is only the first step. With thousands of children successfully reaching remission, the focus must expand to encompass lifelong survivorship care.

Pediatric cancer therapies, including intensive chemotherapy and radiation, can cause late-emerging adverse effects months or even years after completion. These “late effects” may include:

• Growth and endocrine developmental delays

• Cardiac complications and cardiotoxicity

• Fertility impairment

• Cognitive and learning difficulties

• Secondary primary malignancies

“Survivorship care plans, regular follow-up schedules, and robust referral networks are just as crucial as the initial chemotherapy or surgical interventions,” notes pediatric oncology specialists. Ensuring that children not only survive but thrive requires structured monitoring systems that persist well into adulthood.

Study Limitations and Methodological Context

While providing unprecedented insights, the researchers noted several inherent limitations to the study design:

• Publication Bias: The review relies on published literature. Specialized tertiary centers with comprehensive electronic health records and superior clinical outcomes are more likely to publish data than under-resourced rural hospitals, potentially skewing pooled survival estimates upward.

• Geographic Disparities: Pooled national data can obscure regional variations in healthcare access, diagnostic capabilities, and socioeconomic factors that influence treatment completion.

• Registry Gaps: The analysis reflects a synthesis of published literature rather than data from a centralized, mandatory nationwide pediatric cancer registry.

Actionable Takeaways for Families

For parents and caregivers, these studies offer both reassurance and actionable guidance. Childhood cancer is increasingly treatable, but early diagnosis and treatment adherence remain paramount.

Healthcare providers advise parents to seek prompt medical evaluation if a child exhibits persistent, unexplained symptoms, such as:

• Prolonged, unexplained fever or unusual fatigue

• Sudden, unexplained weight loss or loss of appetite

• Persistent bone pain, joint pain, or limping

• Unexplained lumps, swelling, or mass in the abdomen, neck, or extremities

• Visual changes, white pupillary reflex (“cat’s eye” appearance), or new squinting

Furthermore, for families whose children have completed cancer treatment, remaining active in post-treatment survivorship programs is essential for catching late effects early, when they are most manageable.

References

https://www.ndtv.com/health/aiims-delhi-led-study-shares-key-insights-on-childhood-cancer-survival-11824156

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.